Post by Takeda

Name: We're pleased to share topline results from our pivotal Phase 2/3 study for an investigational subcu
Uploaded: 2026-05-04T12:15:38.835Z
Channel: Takeda
Description: We're pleased to share topline results from our pivotal Phase 2/3 study for an investigational subcutaneous immunoglobulin (IG) treatment for people living with Primary Immunodeficiency (#PID). Read

1,702,695 followers

We're pleased to share topline results from our pivotal Phase 2/3 study for an investigational subcutaneous immunoglobulin (IG) treatment for people living with Primary Immunodeficiency (#PID). Read more here: https://lnkd.in/eQwpJR8s

Video Content